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Abstract
Background: Our objective was to measure myelodysplastic syndrome (MDS) and acute myelogenous leukemia
(AML) risk associated with radiation and/or chemotherapy breast cancer (BC) treatment.
Methods: Our study cohort was composed of BC patients diagnosed from 1990 to 2005 and followed up for
blood disorders, mean length of follow up = 7.17 years, range 2-18 years. 5790 TNM stage 0-III patients treated
with surgery alone, radiation and/or chemotherapy were included. Patients without surgery (n = 111), with stem
cell transplantation (n = 98), unknown or non-standard chemotherapy regimens (n = 94), lost to follow up (n = 66)
or ‘cancer status unknown’ (n = 67) were excluded. Rates observed at our community based cancer care institution
were compared to SEER incidence data for rate ratio (RR) calculations.
Results: 17 cases of MDS/AML (10 MDS/7 AML) occurred during the follow up period, crude rate .29% (95% CI = .17,
.47), SEER comparison RR = 3.94 (95% CI = 2.34, 6.15). The RR of MDS in patients age < 65 comparing our cohort
incidence to SEER incidence data was 10.88 (95% CI = 3.84, 24.03) and the RR of AML in patients age < 65 was 5.32
(95% CI = 1.31, 14.04). No significant increased risk of MDS or AML was observed in women ≥ 65 or the surgery/
chemotherapy-only group. A RR of 3.32 (95% CI = 1.42, 6.45) was observed in the surgery/radiation-only group and a RR
of 6.32 (95% CI = 3.03, 11.45) in the surgery/radiation/chemotherapy group. 3 out of 10 MDS cases died of disease at an
average 3.8 months post diagnosis and five of seven AML cases died at an average 9 months post diagnosis.
Conclusions: An elevated rate of MDS and AML was observed among breast cancer patients < 65, those treated
with radiation and those treated with radiation and chemotherapy compared to available population incidence
data. Although a small number of patients are affected, leukemia risk associated with treatment and younger age is
significant.
Background
Breast cancer survival rates have improved over time with
better chemotherapy and radiation treatment options and
guidelines based on diagnostic tumor characteristics [1,2].
Leukemia after breast cancer treatment remains a concern
for survivors but has been a rare event with incidence
rates well documented in a variety of study settings [3-5].
Treatment-related translocation errors have been asso-
ciated with the use of chemotherapy, especially alkylating
agents and anthracyclines [6,7]. Current studies have
linked secondary leukemia occurrence to older age [8-10],
chemotherapeutic agents and dosage (epirubicin, doxoru-
bicin and cyclophosphamide) [11,12], radiation treatment
[13] and supportive treatment with granulocyte stimulat-
ing growth factor (GCSF) [14-16].
The peak incidence of leukemia post adjuvant che-
motherapy has been reported most likely in the first 1-2
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with alkylating agents based on studies of chemotherapy
related translocation errors in myelodysplastic syndrome
(MDS) and acute myelogenous leukemia (AML) [17].
Current studies of radiation induced malignancies sug-
gest a latency time frame of 1-5 years to occurrence of
myeloid leukemia [18,19].
MDS first became a Surveillance, Epidemiology, and End
Results (SEER) reportable cancer in 2001. A study by De
Roos et al found 26% of MDS cases had previous cancer
diagnoses treated with radiation with an associated
increased risk of death [20]. Chemotherapy is not reported
in the SEER Limited Use Data set, so analysis of che-
motherapy or combination radiation/chemotherapy
related to secondary MDS is not possible. A differential
risk of leukemia related to chemotherapy, radiation, or
both has been reported in studies of leukemia post treat-
ment for Hodgkin’s disease [21-23]. In the current study
we report the incidence of MDS and AML in breast can-
cer patients treated with surgery alone, surgery plus radia-
tion and/or chemotherapy and compare the rates to those
obtained from SEER incidence data.
Methods
A breast cancer registry of patients seen at our institu-
tion was created in 1990 containing detailed information
on diagnosis, staging, surgery, chemotherapy, radiation
therapy, tumor markers, and follow up status. Registry
follow up is updated annually by a certified cancer regis-
trar with information on recurrence, subsequent treat-
ment and vital status, current through 2007. Vital and
disease status information is obtained from chart review
if the patient is still seen at the Institution, or through
physician directed follow up letter if follow up care is
provided elsewhere. Patients not under the care of a
managing physician are contacted by mail using an IRB
approved letter from their diagnosing physician request-
ing annual follow up information. If no response is
received, the institution’s cancer registry and the SEER 9
Seattle-Puget Sound Registry are reviewed for patient’s
vital and disease status [24]. Only IRB approved meth-
ods were used for patient follow up and data was input
and stored in a password protected HIPAA compliant
database. All analyses were conducted using de-identi-
fied data as per IRB and HIPAA guidelines. This project
was reviewed and approved by the Institutional Review
Board at our community based regional cancer center.
Patients who did not undergo surgery (n = 111),
patients with incomplete chemotherapy records or non-
standard treatment (n = 23+71 = 94), patients who
underwent stem cell transplants (n = 98), were lost to fol-
low up (n = 66) or had cancer status unknown at follow
up (n = 67) were excluded. The analytic dataset included
women who were treated for stage 0-III (AJCC 6) pri-
mary breast carcinoma and who had a minimum follow-
up duration of 24 months [25]. The cohort of patients
with a minimum follow up duration of two years was
equal to 5,790.
A data review was done of the SEER 9 Seattle-Puget
Sound Registry (SEER 9 S-PS) for all non-multiple mye-
loma bone marrow malignancies post breast cancer diag-
nosis of our registry patients to confirm complete
ascertainment of MDS, AML or other leukemia occur-
rence. We included cases of MDS (histologic type ICD-O-
3 codes 9980, 9982-9987, 9989), AML (histologic type
ICD-O-3 codes 9840, 9861, 9866-9867, 9871-9874, 9895-
9897, 9910, 9920), chronic lymphocytic leukemia (CLL)
(histologic type ICD-O-3 codes 9823), chronic myelogen-
ous leukemia (CML) (histologic type ICD-O-3 codes 9863,
9875, 9876, 9945, 9946) and acute lymphocytic leukemia
(ALL) (histologic type ICD-O-3 codes 9826, 9835-9837)
[26]. Cases previously identified as refractory anemia with
excess blasts (RAEB) were coded as MDS 9983.
Crude cumulative incidence rates were calculated for the
two and five year follow-up cohorts. Chemotherapy regi-
mens were reviewed and classified as either anthracyline-
containing or non-anthracycline-containing regimens for
the purpose of this analysis. For time to leukemia diagno-
sis, observation time began on the breast cancer diagnosis
date and censoring occurred on the leukemia diagnosis
date, date of death or date of last follow-up. Time from
treatment to leukemia diagnosis date was recalculated for
two surgery only patients subsequently treated with che-
motherapy and radiation for recurrence.
Expected age adjusted incidence rates per 100000 per-
son years were calculated using SEERstat version 6.5.2
software (NCI) with cases identified from SEER 9 S-PS
for years 2001-2005 for MDS and 1990-2006 for AML,
CML, ALL, and CLL [24]. MDS cases were identified
using ICD-O-3 codes matched to the SEERstat recode
ICD-O-3 list [26,27]. Observed age adjusted incidence
rates by person-years were calculated using the number
of events divided by the total number of person years of
follow-up with exact 95% confidence intervals obtained
from the Poisson distribution [28]. Cumulative 15 year
incidence rates of MDS/AML were calculated with
adjustment for survival using Kaplan-Meier plots [29].
Ninety-five percent confidence intervals (CIs) for cumu-
lative incidence were calculated using the bootstrap
method; use of arcsine and logarithmic methods yielded
highly similar results [30]. Cox regression analysis was
used to assess the relationship between age and treat-
ment and time to MDS/AML incidence [29]. Interval
from breast cancer diagnosis to MDS/AML incidence by
treatment groups was calculated using the Kaplan Meier
method [29].
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Average patient age was 57 years, range 21-94 years
and average follow up for patients alive at follow up
was 7.16 years, range 2-18 years. 69% (n = 4,014) of
the cohort were less than age 65 and 31% (n = 1,776)
were 65 or older (table 1). The total number of person
years analyzed was 40,650, with patients diagnosed in
1998 contributing the most person years. We included
TNM stage 0-III with 13% stage 0, 45% stage I, 35%
stage II, and 7% stage III. 420 patients were treated
with surgery only (7%), 2764 had surgery/radiation
therapy (48%), 640 had surgery/chemotherapy (11%)
and 1966 had combined surgery/radiation/chemother-
apy treatment (34%). Treatment received differed sig-
n i f i c a n t l yb ya g e<6 5a n d≥ 65 (chi square = 920.17, p
< .001). Surgery only and surgery/radiation were
roughly equivalent between the two age groups but
only 8% of the surgery/chemotherapy group was 65
and older and 12% of the surgery/radiation/chemother-
apy group was 65 or older. Eighty percent of che-
motherapy patients received one of four standard
treatments: 1) anthracycline and cyclophosphamide
(AC) (19%), 2) cyclophosphamide, anthracycline and
fluorouracil (CAF) (13%), 3) cyclophosphamide, metho-
trexate and fluorouracil (CMF) (22%), and 4) AC with
a taxane (26%). 76% of chemotherapy patients received
anthracyclines (n = 1,973). Nine hundred seventy two
of 2,081 chemotherapy patients (46.7%) received G-
CSF in varying amounts during chemotherapy
treatment.
There were 17 incident cases of MDS/AML with ten
MDS cases (7 with initial treatment only/no treatment
for recurrence and three cases with initial treatment/
treatment for recurrence) and 7 AML cases (5 cases
initial treatment/no treatment for recurrence and two
treatment related AML initially diagnosed as MDS pro-
gressing to AML, one of which was treated for recur-
rence). The median age at breast cancer diagnosis of the
MDS/AML patients was 57 years (range 33-76 years)
with no significant difference in distribution of MDS/
AML incidence by age. Two patients had surgery only
for initial treatment with subsequent radiation and che-
motherapy for recurrent disease, seven had surgery/
radiation, one had surgery/chemotherapy and seven had
surgery/radiation/chemotherapy treatment. The two sur-
gery only patients were < 65, the surgery/chemotherapy
patient was ≥ 65, two of the 7 surgery/radiation patients
were < 65 and six of the 7 surgery/radiation/chemother-
apy patients were < 65 (chi square = 7.56, p = .056). Of
the 16 MDS/AML patients receiving radiation therapy
all were standard dose of either 5000-5580 centi-Gray
units (cGy) with a 1000-1440 cGy boost or 4500-4680
cGy with a 1400 cGy boost delivered at a number of dif-
ferent local radiation facilities. Two patients were admi-
nistered an additional 4860-5040 cGy to the lymph
nodes.
Median survival of MDS/AML patients post diagnosis
was 9 months, range .5 to 134 months. Median survival
for the seven ‘alive at follow up’ MDS patients was 21
months, range 8-75 months. Three of the 10 MDS post
breast cancer patients died of MDS at an average of 3.8
months post MDS diagnosis, range .5-8 months and five
of the seven AML post breast cancer patients died of
AML at a median of 8 months post AML diagnosis (Fig-
ure 1).
Cytogenetic reports were available on five of 17 MDS/
AML patients. One patient demonstrated an 11q23
translocation, consistent with anthracycline induced
acute leukemia [6]. Another patient had chromosome 5
and 7 abnormalities consistent with alkylating agent-
induced acute leukemia, as well as de novo leukemia
and MDS [31].
Table 1 Descriptive Statistics (n = 5790)
Variable
Age: mean (range) 57.40 (21-94)
TNM Stage: N (%)
0 736 (12.7%)
I 2625 (45.3%)
IIa 1298 (22.4%)
IIb 729 (12.6%)
IIIa 239 (4.1%)
IIIb 116 (2.0%)
IIIc 47 (.8%)
Estrogen receptor positive 4268 (73.7%)
Progesterone receptor positive 3628 (62.7%)
Treatment: N (%)
Surgery only 420 (7.3%)
Surgery/radiation 2764 (47.7%)
Surgery/chemotherapy 640 (11.1%)
Surgery/radiation/chemotherapy 1966 (34.0%)
Anthracycline regimen 1973 (75.7%)
Non-anthracycline regimen 646 (24.3%)
Tamoxifen 3554 (61.4%)
Follow up years: mean (range) 7.02 (.20, 18.15)
Vital Status: N (%)
Alive, NED* 4741 (81.9%)
Alive with this cancer 123 (2.1%)
Alive with other cancer 62 (1.1%)
Expired, NED 354 (6.1%)
Expired with this cancer 388 (6.7%)
Expired with other cancer 121 (2.1%)
Expired, treatment complications 1 (.0%)
*NED: no evidence of disease
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diagnosis was 4.35 years, range .67-13.6 years. Median time
from treatment with radiation or chemotherapy was 3.06
years, range = .41-12.95 years. The latter number takes
into account the chemotherapy and radiation treatment
start dates for the two surgery only patients that had recur-
rences and the treatment start date instead of the breast
cancer diagnosis date for the other 15 patients. A paired
samples t-test comparison of mean time to leukemia inci-
dence post initial or first recurrence treatment for the two
surgery only initial treatment patients was not significant.
In our cohort, two patients developed CML, two ALL,
and five CLL (n = 9) (table 2). Average age at diagnosis
was 73 years, range 53 to 88 years. The CLL, ALL and
one of the two CML patients were diagnosed with leu-
kemia at ≥ 65 years of age. Eight out of nine received
surgery/radiation treatment, one had surgery only and
none had chemotherapy as initial treatment. Average
time from breast cancer diagnosis to CML, ALL, or CLL
diagnosis was 4.92 years, range .25 to 8.92 years.
We calculated crude incidence rates of MDS/AML
and all leukemia types (MDS, AML, CML, CLL, ALL)
for two and five year minimum follow up by treatment
combinations (tables 3 and 4). Crude rate of MDS/AML
incidence was .29% (95% CI = .17, .47). By treatment
category with minimum 2 years follow up the crude
rates were .25 (7/2764) surgery/radiation (95% CI = .10,
.52), .16 (1/639) surgery/chemotherapy (95% CI = .00,
.87) and .46 (9/1959) surgery/radiation/chemotherapy
(95% CI = .21, .87). No difference in MDS/AML was
observed in the anthracycline compared to the non-
anthracycline adjuvant chemotherapy treatment group.
C r u d ea l ll e u k e m i ai n c i d e n c er a t e( M D S ,A M L ,C M L ,
CLL, ALL) was .45% for two year minimum follow up.
Crude rates of MDS/AML or combined all leukemia did
not differ significantly by treatment regimen. Using
Kaplan-Meier one-minus-survival curve estimates, the 5-
year MDS/AML cumulative incidence rate was .20%, the
10-year rate was .50% and the 15-year rate was .70%
(Figure 2).
Ten cases of MDS occurred during the follow up per-
iod compared to 2.72 expected from SEER 9 S-PS age
adjusted rates. The SEER expected MDS incidence rate
for women < 65 years was 1.6/100000 and our observed
rate was 17.5/100000, RR = 10.88 (95% CI = 3.84, 24.03)
(table 5). The SEER expected MDS incidence rate for
women ≥ 65 years was 31.6/100000 and the observed
rate was 41.6/100000, RR = 1.31 (95% CI = 0.47, 2.84).
The SEER expected AML incidence rate for women <
65 years was 2.0/100000 and the observed rate was
Table 2 CML/CLL/ALL Case Description (n = 9)
Age at
dx
Disease stage at
dx
Chemotherapy Radiation Leukemia
Type
Time from breast dx to leukemia
(months)
Time from leukemia
dx to last fu
(months)
79 I none yes CLL 37 57 (Alive)
64 I none yes CLL 61 56 (Dec.)
74 I none yes CLL 96 20 (Alive)
61 II None no CLL 79 109 (Alive)
58 I None yes CLL 110 70 (Alive)
50 I recurrence
1993
yes CML 33 9 (Dec.)
73* I None yes CML 3 14 (Dec.)
76 II None yes ALL 38 19 (Dec.)
81 I None yes ALL 81 4 (Dec.)
* Cytogenetics: Philadelphia chromosome resulting from a 9;22 translocation designated as 46, XX, t(9;22)(q34;q11 2).
Figure 1 Survival time in months post myelodysplastic
syndrome/acute myelogenous leukemia diagnosis after
treatment for primary breast cancer (n = 17).
Kaplan et al. BMC Cancer 2011, 11:260
http://www.biomedcentral.com/1471-2407/11/260
Page 4 of 1010.5/100000, RR = 5.32 (95% CI = 1.32, 14.04). The
SEER expected AML incidence rate for women ≥ 65
years was 14.0/100000 and the observed rate was 33.3/
100000, RR = 2.38 (95% CI = 0.73, 5.61). Overall, 17
cases of MDS/AML (10 MDS/7 AML) occurred during
the follow up period compared with 4.29 expected based
on SEER rates (RR = 3.94, 95% CI = 2.34, 6.15).
Comparing the rate of MDS/AML in our cohort by
treatment category to the SEER 9 S-PS region MDS/
AML incidence rates, the rate ratio among patients trea-
ted with surgery/radiation (n = 7) was 3.32 (95% CI =
1.42, 6.45) and surgery/radiation/chemotherapy (n = 9)
was 6.32 (95% CI = 3.03, 11.45). No cases of MDS/AML
were observed in the surgery only group and one case
occurred in the surgery/chemotherapy group (RR =
1.88, 95% CI = .11, 8.30) (table 6). MDS/AML incidence
distribution was not significantly different by age but
treatment received was significantly different by age
with younger patients receiving more chemotherapy. In
a Cox regression model measuring time to leukemia
diagnosis in months and correcting for age, initial treat-
ment was not significant in the model (n = 5,790), (-2
log likelihood = 270.52, chi square = 3.65, 2 degrees of
freedom, p = .456). Due to zero cases of MDS/AML in
the surgery only group when the groups including treat-
ment for recurrence were used, a second model could
not be run. In survival analysis the four treatment
groups did not differ significantly from time of initial
breast cancer diagnosis to time of MDS/AML diagnosis
(log rank test = 4.327, p = .226) with the majority of the
surgery/radiation/chemotherapy group MDS/AML inci-
dence occurring within 5 years of treatment (n = 7)
(Figure 3). There was no significant difference in leuke-
mia incidence by GCSF treatment with 972/2081 che-
motherapy patients treated with GCSF, Pearson chi
square = .877, p = .349.
Discussion
We found a statistically significant increased risk of MDS
and AML among post treatment breast cancer patients
Table 3 Crude MDS/AML rates by treatment category
Treatment category % (cases/no. in category) (95% CI)
2 years of follow up (n = 5790)
All patients .29 (17/5790) (.17, .47)
Surgery only 0 (0/420) (0)
Surgery/radiation .25 (7/2764) (.10, .52)
Surgery/chemotherapy .16 (1/639) (.00, .87)
Surgery/radiation/chemotherapy .41 (9/1959) (.21, .87)
Anthracycline regimen .25 (5/1968) (.08, .59)
Non-anthracycline regimen .47 (3/633) (.10, 1.38)
5 years of follow up (n = 4179)
All patients .41 (17/4179) (.24, .65)
Surgery only 0 (0/222) (0)
Surgery/radiation .24 (5/2058) (.08, .57)
Surgery/chemotherapy .22 (1/461) (.01, 1.20)
Surgery/radiation/chemotherapy .42 (6/1440) (.15, .90)
Anthracycline regimen .15 (2/1368) (.02, .53)
Non-anthracycline regimen .56 (3/531) (.12, 1.64)
Table 4 Crude all leukemia rates by initial treatment
category (MDS, AML, CML, CLL, ALL)
Treatment category % (cases/no. in category) (95% CI)
2 years of follow up (n = 5790)
All patients .45 (26/5790) (.29, .66)
Surgery only .24 (1/418) (.01, 1.33)
Surgery/radiation .54 (15/2764) (.30, .89)
Surgery/chemotherapy .16 (1/640) (.00, .87)
Surgery/radiation/chemotherapy .46 (9/1968) (.21, 1.64)
5 years of follow up (n = 4179)
All patients .50 (21/4179) (.31, .77)
Surgery only .45 (1/220) (.01, 2.51)
Surgery/radiation .63 (13/2058) (.34, 1.08)
Surgery/chemotherapy .22 (1/461) (.01, 1.20)
Surgery/radiation/chemotherapy .42 (6/1440) (.15, .90)
5790            3520             1334               257    
No. at risk
Figure 2 15 year cumulative incidence of myelodysplastic
syndrome/acute myelogenous leukemia (n = 17).
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in risk is significantly higher than expected in the general
population when we compare our rates to those for the
same age and gender using SEER data, the rate represents
a small actual number of affected patients (17/5790,
.29%) Three of the ten MDS patients (30%) and 5 of the
7 AML patients (71%) died of disease. The risk of MDS
in women < 65 years of age was 11 times higher than
SEER 9 S-PS estimates and risk of AML in women < 65
was 5 times higher. While the incidence of AML/MDS
was substantial among women aged 65 and over, it was
not statistically significant. This is perhaps due to a
higher background incidence rate of MDS/AML in
women 65 and older. A three-fold increase in risk was
observed among patients treated with radiation alone and
a six fold increase in risk among patients treated with
radiation and chemotherapy indicating a possible syner-
gistic effect of radiation and chemotherapy.
There was no increased risk of MDS/AML in the sur-
gery/chemotherapy group or the surgery only group.
Both of these groups were small in number and repre-
sented a small percentage of the total cohort, treatment
with surgery only at 7% (n = 420) and surgery/che-
motherapy at 11% (n = 640). With a limited number of
chemotherapy only patients even with many years of fol-
low-up it is unlikely we would be able to ascertain a
small increased risk if it is present.
The strengths of our study are the following: complete
case ascertainment with follow up from our registry and
linkage to the Seattle-Puget Sound SEER database, com-
plete treatment information on each patient, inclusion
of MDS diagnosis, a large cohort with substantial follow
Table 5 Expected and observed incidence rates of MDS/AML by age per 100000 person years.
Leukemia
Type
Age Expected
Rate*
Person
years
Observed
Rate
Expected
Cases
Observed
Cases
Rate Ratio
(95% CI)
MDS < 65 1.6 28538 17.5 0.46 5 10.88
(3.84, 24.03)
≥ 65 31.6 12027 41.6 3.80 5 1.31
(0.47, 2.84)
All 6.7 40565 24.7 2.71 10 3.70
(1.85, 6.54)
AML < 65 2.0 28538 10.5 0.57 3 5.32
(1.31, 14.04)
≥ 65 14.0 12027 33.3 1.68 4 2.38
(0.73, 5.61)
All 4.0 40565 17.3 1.62 7 4.32
(1.85, 8.45)
MDS/AML < 65 3.6 28538 28.1 1.03 8 7.82
(3.54, 14.77)
≥ 65 45.6 12027 74.8 5.48 9 1.64
(0.79, 2.98)
All 10.6 40565 41.9 4.30 17 3.94
(2.34, 6.15)
*SEER 9 incidence rates, Seattle-Puget Sound Region [24]
Table 6 Expected and observed incidence rates of MDS/AML by treatment group per 100,000 person years
Expected
Rate*
Person
years
Observed
Rate
Expected
Cases
Observed
Cases
Rate Ratio
(95% CI)
SEER 9 S-PS 10.6 ———————— ———————— ———————— ———————— ————————
Surgery only 10.6 2525 0 .27 0 0
Surgery/
radiation
10.6 19776 35.4 2.10 7 3.32
(1.42, 6.45)
Surgery/
chemotherapy
10.6 4985 20 .53 1 1.88
(0.11, 8.30)
Surgery/
radiation/
chemotherapy
10.6 13365 67.3 1.42 9 6.32
(3.03, 11.45)
All treatment categories 10.6 40565 41.9 4.30 17 3.94
(2.34, 6.15)
*The SEER 9 incidence rate age 20-80+ for MDS/AML was used for the comparison rate for all treatment categories, Seattle-Puget Sound Region [24]
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of index patients. In our previous report on leukemia
post breast cancer a comparison group with specific
incidence of MDS and AML was not as yet available
from SEER data. In our current analysis we report the
treatment specific crude rates and rate ratios using the
SEER population data for comparison. We have also
moved the two patients treated initially with surgery
only into the appropriate post recurrence treatment
category, leaving the surgery only group without any
cases. A larger cohort or perhaps longer follow up
such as we have now may be necessary to characterize
rates of treatment related MDS/AML using a popula-
tion based comparison group [5]. We did not observe
an association of increased risk with anthracycline
therapy previously or in the current study. We did not
find an association with GCSF treatment, despite the
fact that this possibility has been suggested in other
studies [14].
A limitation of our study is the absence of cytogenetic
studies on all patients which if available can confirm
treatment related leukemia. Time proximity from pri-
mary breast cancer to MDS/AML occurrence may indi-
cate treatment related disease. The two cases with
questionable time from treatment to leukemia incidence
were one AML patient with less than 1 year post treat-
ment and one patient with greater than 10 years post
treatment both of whom were over 75 years of age. A
very short (< 1 year) or very long latency period (>10
years) post treatment may indicate non-treatment
related disease especially in an older adult. Our compar-
ison of leukemia incidence post treatment by che-
motherapy regimen received may lack power due to
most patients (80%) receiving an anthracycline based
therapy and a much smaller number receiving non-
anthracyline chemotherapy. This is the first study mea-
suring MDS and comparing incidence of MDS post
breast cancer treatment to nationally reported rates. A
Figure 3 Time in years from categorical breast cancer treatment to diagnosis of myelodysplastic syndrome or acute myelogenous
leukemia (n = 17).
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MDS as it is a newly reportable disease which may
inflate the risk ratio comparison. Although this is a pos-
sibility we sought to reduce the chance by using rates
from the same area in which the community based can-
cer treatment center is located.
Martin et al in their SEER data analysis of AML in
breast cancer survivors found an increased risk of AML
in younger women with stage III compared to stage I
disease (< 50 and 50-64 years of age) but not in older
women (65 and older) as we have in the present study
[32]. Among the AML cases (n = 7), 3 had a stage III
diagnosis, age 63, 64, and 65 years. All MDS cases in
our cohort (n = 10) occurred in women diagnosed with
stage 0-II breast cancer. Mar t i ne ta lf o u n dr i s ko fp o s t
treatment AML to be associated with age younger than
65 which has also been reported in a National Cancer
Institute study of new malignancies following breast
cancer [32,33]. The NCI study group reported an
increased risk of acute non-lymphocytic leukemia in
younger vs. older women with overall peak risk for all
ages occurring 1-4 years post diagnosis of breast cancer
[33]. Risk was highest among women less than 40 years
of age and increased risk continued until >10 years of
follow up with no increased risk at ages greater than 70
years.
An increased risk of leukemia associated with combi-
nation radiation and chemotherapy treatment has been
reported from randomized clinical trials (RCTs) with
comprehensive follow up of study participants for leuke-
mia post breast cancer treatment [4,11,12,34-37]. Renella
et al evaluated the risk of AML only post breast cancer
treatment among a cohort of 6360 patients diagnosed
between 1970 and 1999 and followed to 2000 finding a
cumulative risk of AML equal to 0.20%, a 3.5-fold
increased risk over the general population [38]. Risk was
significantly increased among women greater than 70
years of age and those treated with radiotherapy. In a
case-control study within a cohort an increased risk of
acute non-lymphocytic leukemia was found among
patients treated with regional radiotherapy alone, alky-
lating agents alone and combined radiation and che-
motherapy with the highest risk ratio among radiation/
chemotherapy patients [3]. The effect of radiation is not
well characterized from summaries of study results as
most observations are drawn from randomized clinical
trials that do not include radiotherapy only patients and
do not include identification of MDS.
We did observe a number of cases of ALL, CML, and
CLL in our patient population post breast cancer treat-
ment. All but one of these patients received radiation
therapy for their breast cancers. Each of these diseases
has been associated with exposure to ionizing radiation,
although there has been some uncertainty with regard
to CLL [39-41]. However, the number of cases in our
cohort is too small to allow us to draw any additional
conclusions.
Only a few cohort studies have been conducted which
include radiation treatment patients as a separate group
[3,38]. In a review of the epidemiologic literature, ioniz-
ing radiation exposure has been linked to cancer with
leukemia being particularly sensitive to induction espe-
cially at younger ages [42]. Radiation can interact with
other carcinogens such as chemotherapeutic agents and
host factors such as age. Therefore combination therapy
may confer a higher risk of secondary leukemia in
younger vs. older women which may offer another
explanation for our observed absence of increased risk
in older women. The increased risk among women less
than age 65 treated with radiation suggests a possible
role of radiation in the pathogenesis of treatment related
AML and MDS. Previously reported leukemic effects of
chemotherapy may have been more compelling with
daily oral dosing and higher cumulative doses of cyclo-
phosphamide given in the past, as well as the use of
agents such as melphalan, which appears to be more
leukemogenic than other alkylating agents [3,36]. Cur-
rent intermittent drug administration at lower cumula-
t i v ed o s e sm a yn o tb ea sl e u k e m o g e n i ca sp a s t
treatment regimens and we did not observe any
increased risk in the smaller group of chemotherapy
only patients. The finding of a higher risk associated
with radiation and chemotherapy combination therapy
as opposed to either modality alone has also been
reported in the treatment of Hodgkin’s disease [23].
Conclusions
Our findings suggest an increased risk of MDS/AML
with radiation treatment in this patient population. An
increased risk related to radiation therapy raises a num-
ber of issues. First, it would add another dimension to
the question of whether a woman might choose a mas-
tectomy as opposed to lumpectomy followed by radia-
tion, especially if she is to receive adjuvant
chemotherapy. Second, it raises the question of whether
or not differential radiation exposure from partial breast
irradiation techniques as opposed to more traditional
techniques might change the radiation-induced risk of
MDS/AML.
Current diagnosis and treatment patterns include
more early stage disease and an increase in the number
and percent of patients treated with radiation only post
surgery, especially among younger women [43]. Recent
studies suggest that carcinogenesis related to radiation
exposure may have different mechanisms at different
ages, leaving younger women more susceptible to tumor
promotion than older women [44]. An increased risk of
treatment related leukemia in younger age groups more
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Page 8 of 10susceptible to the promotion effect of radiation adds
urgency to the exploration of factors which differentiate
DCIS and early stage invasive breast cancer cases that
require aggressive therapy from those that do not
[45-47]. Although the absolute number of MDS/AML
post breast cancer treatment is small, the risk of post
treatment leukemia must be considered in the choice of
therapy for breast cancer patients. Future studies of
MDS and AML incidence post radiation and che-
motherapy are needed to fully inform patients, survivors
and physicians of treatment risk.
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